Lifesci Capital Brokers Lower Earnings Estimates for PRAX

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Research analysts at Lifesci Capital lowered their Q2 2026 earnings estimates for shares of Praxis Precision Medicines in a research report issued to clients and investors on Friday, May 8th. Lifesci Capital analyst F. Brisebois now expects that the company will earn ($3.46) per share for the quarter, down from their previous forecast of ($3.37). The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($15.16) per share. Lifesci Capital also issued estimates for Praxis Precision Medicines’ Q3 2026 earnings at ($3.63) EPS, Q4 2026 earnings at ($3.79) EPS and FY2026 earnings at ($14.07) EPS.

Other analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $1,245.00 price target on shares of Praxis Precision Medicines in a report on Tuesday, April 7th. Wells Fargo & Company set a $305.00 price target on shares of Praxis Precision Medicines and gave the company an “equal weight” rating in a report on Friday, February 20th. Needham & Company LLC reissued a “buy” rating and issued a $510.00 price target on shares of Praxis Precision Medicines in a report on Tuesday, April 14th. TD Cowen reissued a “buy” rating on shares of Praxis Precision Medicines in a report on Thursday, January 29th. Finally, Piper Sandler reissued an “overweight” rating and issued a $1,200.00 price target (up from $450.00) on shares of Praxis Precision Medicines in a report on Wednesday, January 28th. Five research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Praxis Precision Medicines presently has a consensus rating of “Buy” and an average price target of $591.83.

Praxis Precision Medicines Trading Up 0.5%

NASDAQ:PRAX opened at $331.81 on Tuesday. Praxis Precision Medicines has a 1 year low of $35.21 and a 1 year high of $356.00. The firm’s fifty day simple moving average is $317.26 and its 200 day simple moving average is $279.65. The firm has a market capitalization of $9.25 billion, a PE ratio of -24.82 and a beta of 2.76.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its earnings results on Thursday, May 7th. The company reported ($3.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.58) by $0.38.

Hedge Funds Weigh In On Praxis Precision Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the business. Parallel Advisors LLC lifted its holdings in shares of Praxis Precision Medicines by 3,000.0% during the 1st quarter. Parallel Advisors LLC now owns 124 shares of the company’s stock worth $40,000 after acquiring an additional 120 shares during the period. NBC Securities Inc. bought a new position in shares of Praxis Precision Medicines during the 4th quarter worth about $38,000. Danske Bank A S bought a new position in shares of Praxis Precision Medicines during the 4th quarter worth about $59,000. GAMMA Investing LLC lifted its holdings in shares of Praxis Precision Medicines by 58.7% during the 4th quarter. GAMMA Investing LLC now owns 238 shares of the company’s stock worth $70,000 after acquiring an additional 88 shares during the period. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Praxis Precision Medicines by 60.0% during the 4th quarter. Farther Finance Advisors LLC now owns 368 shares of the company’s stock worth $108,000 after acquiring an additional 138 shares during the period. 67.84% of the stock is owned by institutional investors.

Key Praxis Precision Medicines News

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Praxis Precision Medicines and reiterated a $1,245 price target, while also nudging up its FY2028 and FY2029 earnings estimates, signaling strong confidence in the company’s long-term potential.
• Positive Sentiment: TipRanks highlighted Praxis Precision Medicines’ “high-stakes launch path” after its Q1 earnings call, suggesting investors are focused on the company’s upcoming commercialization efforts and potential catalyst from its pipeline. Article Title
• Neutral Sentiment: Lifesci Capital lowered its 2026 EPS estimates for PRAX across Q2, Q3, Q4, and full-year 2026, reflecting a more cautious near-term view on earnings, even though the firm did not change the broader story materially.
• Neutral Sentiment: HC Wainwright also trimmed its 2026 and 2027 earnings forecasts, but its long-term estimates remain sharply positive, indicating the revisions are more about timing than a change in the thesis.
• Negative Sentiment: Wedbush reportedly maintained an Underperform rating and flagged concerns about the ulixacaltamide filing, which may be weighing on sentiment by highlighting execution and regulatory risk. Article Title

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.